Clinical trials of endothelin antagonists in heart failure: Publication is good for the public health

Heart

Volumn 93, Issue 1, 2007, Pages 2-4

  Kelland, N F ^a   Webb, D J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; BOSENTAN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; NITRIC OXIDE; PLACEBO; PROSTACYCLIN;

CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CIRCULATION; CLINICAL TRIAL; EDITORIAL; ENDOTHELIUM CELL; HEART FAILURE; HEMODYNAMICS; HUMAN; NATRIURESIS; PRIORITY JOURNAL; PUBLIC HEALTH; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; ENDOTHELIN-1; EVIDENCE-BASED MEDICINE; HEART FAILURE, CONGESTIVE; HUMANS; PUBLISHING; RECEPTOR, ENDOTHELIN A;

EID: 33846221367     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.089250     Document Type: Editorial

References (44)

1. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405.
2. Sato K, Oka M, Hasunuma K, et al. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 1995;269:L668-72.
3. MacLean MR, McCulloch KM, Baird M. Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol 1994;23:838-45.
4. Attina T, Camidge R, Newby DE, et al. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 2005;91:825-31.
5. Cannan CR, Burnett JC Jr, Lerman A. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation 1996;93:646-51.
6. Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199:1461-5.
7. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186- 93.
8. Cowburn PJ, Cleland JG. Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J 2001;22:1772-84.
9. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-8.
10. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002;106:2666-72.
11. Mytona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1999;1:197-200.
12. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Cardiac Failure 2002;8:124-7.
13. Abrahams W. Progress in clinical trials: ENCOR (Enrasentan Cooperative Randomized Evaluation). Clin Cardiol 2001;24:481-3.
14. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:347-54.
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
16. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971-7.
17. Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-5.
18. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997;96:1976-82.
19. Lee DS, Nguyen QT, Lapointe N, et al. Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure. J Cardiac Failure 2003;9:368-74.
20. Nguyen QT, Cernacek P, Sirois MG, et al. Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation 2001;104:2075-81.
21. Takanashi C, Kagaya Y, Namiuchi S, et al. Nonselective endothelin receptor antagonist initiated soon after the onset of myocardial infarction may deteriorate 24-hour survival. J Cardiovasc Pharmacol 2001;38:29-38.
22. Leslie SJ, Spratt JC, McKee SP, et al. Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure. Heart 2005;91:914-19.
23. McKelvie RS, Rouleau JL, White M, et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 2003;24:1727-34.
24. Cowburn PJ, Cleland JG, McDonagh TA, et al. Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. Eur J Heart Fail 2005;7:37-42.
25. Goddard J, Eckhart C, Johnston NR, et al. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 2004;15:2601-10.
26. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005;111:363-8.
27. Halcox JP, Nour KR, Zalos G, et al. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ Res 2001;89:969-76.
28. Halcox JP. Investigation of the role of endothelin in the regulation of human coronary vascular tone [MD]. Cambridge: University of Cambridge, 2003.
29. Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 2002;54:219-26.
30. Goddard J, Webb DJ. Endothelin antagonists and hypertension: a question of dose? Hypertension 2002;40:e1-2.
31. Spratt JC, Goddard J, Patel N, et al. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 2001;134:648-54.
32. Morris CD, Rose A, Curwen J, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 2005;92:2148-52.
33. Nishikibe M, Ohta H, Okada M, et al. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. J Pharmacol Exp Ther 1999;289: 1262-70.
34. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35.
35. Clozel M, Ramuz H, Clozel JP, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999;290:840-6.
36. Ohlstein EH, Nambi P, Logo A, et al. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 1996;276:609-15.
37. Munter K, Hergenroder L, Unger L, et al. Oral treatment with a selective ETA-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett 1996;6:90-2.
38. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization or A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996;276:473-81.
39. Ishikawa K, Fukami T, Nagase T, et al. Cyclic pentapeptide endothelin antagonists with high ETA selectivity. Potency- and solubility-enhancing modifications. J Med Chem 1992;35:2139-42.
40. Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997;40:1690-7.
41. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet 2004;364:911-12.
42. Drazen JM, Wood AJ. Trial registration report card. N Engl J Med 2005;353:2809-11.
43. Krleza-Jeric K, Chan AW, Dickersin K, et al. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ 2005;330:956-8.
44. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000;101:2922-7.